IDEXX Laboratories (FRA:IX1) ROCE %: 68.21% (As of Mar. 2026)


FRA:IX1 IDEXX Laboratories Inc FRA:IX1
96 GF Score
Price €473.80
GF Value €552.99
Valuation Modestly Undervalued
View Full Analysis

What is IDEXX Laboratories ROCE %?

IDEXX Laboratories FRA:IX1 -0.19% 96 ROCE % is 68.21% as of Mar. 2026. GuruFocus rates FRA:IX1 with a GF Score™ of 96/100 and a GF Value™ of €552.99 (Modestly Undervalued).

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. IDEXX Laboratories's annualized ROCE % for the quarter that ended in Mar. 2026 was 68.21%.

IDEXX Laboratories  (FRA:IX1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

IDEXX Laboratories ROCE % Related Terms

IDEXX Laboratories ROCE % Historical Data

* Premium members only.

The historical data trend for IDEXX Laboratories's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEXX Laboratories ROCE % Chart

IDEXX Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.14 58.43 57.08 51.37 58.12

IDEXX Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.10 69.14 66.45 58.39 68.21
FRA:IX1
96GF Score
IDEXX Laboratories Inc FRA:IX1
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IDEXX Laboratories ROCE % Calculation

IDEXX Laboratories's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=1164.037/( ( (3145.238 - 1019.86) + (2861.548 - 981.087) )/ 2 )
=1164.037/( (2125.378+1880.461)/ 2 )
=1164.037/2002.9195
=58.12 %

IDEXX Laboratories's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=1256.612/( ( (2861.548 - 981.087) + (2928.455 - 1124.371) )/ 2 )
=1256.612/( ( 1880.461 + 1804.084 )/ 2 )
=1256.612/1842.2725
=68.21 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 68.21% mean?
IDEXX Laboratories (FRA:IX1) has a ROCE % of 68.21% as of Mar. 2026.
Is IDEXX Laboratories' ROCE % too high?
IDEXX Laboratories' current ROCE % is 68.21%. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' ROCE % compare to A and WAT?
IDEXX Laboratories' ROCE % of 68.21% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. IDEXX Laboratories's current ROCE % is 68.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €552.99, compared to a current price of €473.80 — trading 14.3% below its estimated fair value. The current ROCE % is 68.21%. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current ROCE % is 68.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?

Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued. The current stock price of €473.80 is trading 14.3% below its estimated GF Value™ of €552.99. GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.

Key valuation signals for FRA:IX1:

  • ROCE %: 68.21%
  • GF Value™: €552.99 vs. price of €473.80 (14.3% below fair value)
  • GF Score™: 96/100

No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IDEXX Laboratories Business Description

Address One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score

Get the complete analysis for FRA:IX1

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€473.80
Price
€552.99
GF Value